
Bristol-Myers Squibb Co
NYSE:BMY

US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
Banking
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
Technology
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
US |
![]() |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
US |
![]() |
Visa Inc
NYSE:V
|
Technology
|
CN |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
US |
![]() |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
Beverages
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
Retail
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
38.5971
63.11
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
![]() |
Johnson & Johnson
NYSE:JNJ
|
US |
![]() |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
![]() |
Bank of America Corp
NYSE:BAC
|
US |
![]() |
Mastercard Inc
NYSE:MA
|
US |
![]() |
UnitedHealth Group Inc
NYSE:UNH
|
US |
![]() |
Exxon Mobil Corp
NYSE:XOM
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
US |
![]() |
Palantir Technologies Inc
NYSE:PLTR
|
US |
![]() |
Nike Inc
NYSE:NKE
|
US |
![]() |
Visa Inc
NYSE:V
|
US |
![]() |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
![]() |
3M Co
NYSE:MMM
|
US |
![]() |
JPMorgan Chase & Co
NYSE:JPM
|
US |
![]() |
Coca-Cola Co
NYSE:KO
|
US |
![]() |
Walmart Inc
NYSE:WMT
|
US |
![]() |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.

Intrinsic Value
The intrinsic value of one
BMY
stock under the Base Case scenario is
72.82
USD.
Compared to the current market price of 59.01 USD,
Bristol-Myers Squibb Co
is
Undervalued by 19%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Bristol-Myers Squibb Co
Uncover deeper insights with the Valuation History. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.

Valuation History
Historical valuation for BMY cannot be conducted due to limitations such as insufficient data or other constraints.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:

Heightened patent-expiration risk and revenue concentration around key drugs like Revlimid and Eliquis could sharply reduce Bristol-Myers Squibb’s cash flows, limiting its ability to fund pipeline development.
Rising competition in the immuno-oncology space, especially from Merck’s Keytruda and Roche’s Tecentriq, threatens market share and pricing power for BMY’s flagship therapies such as Opdivo.
The company’s ambitious R&D strategy, combined with recent large-scale acquisitions, presents integration and execution risks that could weigh on profitability if pipeline candidates fail to deliver expected returns.
Bristol-Myers Squibb holds a leading position in immuno-oncology with proven blockbusters like Opdivo and Yervoy, providing a strong base of recurring revenue and brand recognition.
The combined portfolios from Celgene and MyoKardia acquisitions bolster BMY’s pipeline in oncology and cardiovascular treatments, diversifying revenue streams and driving potential long-term growth.
Robust free cash flow and a strong balance sheet allow for continued investment in novel therapies, strategic partnerships, and share repurchases, signaling potential for sustained shareholder returns.

Revenue & Expenses Breakdown
Bristol-Myers Squibb Co
Balance Sheet Decomposition
Bristol-Myers Squibb Co
Current Assets | 29.8B |
Cash & Short-Term Investments | 10.9B |
Receivables | 14.4B |
Other Current Assets | 4.5B |
Non-Current Assets | 62.8B |
Long-Term Investments | 2.1B |
PP&E | 8.4B |
Intangibles | 45B |
Other Non-Current Assets | 7.4B |
Current Liabilities | 23.8B |
Accounts Payable | 3.6B |
Accrued Liabilities | 13.3B |
Short-Term Debt | 218m |
Other Current Liabilities | 6.6B |
Non-Current Liabilities | 52.5B |
Long-Term Debt | 47.6B |
Other Non-Current Liabilities | 4.9B |
Free Cash Flow Analysis
Bristol-Myers Squibb Co
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Bristol-Myers Squibb Co
Revenue
|
48.3B
USD
|
Cost of Revenue
|
-11.9B
USD
|
Gross Profit
|
36.4B
USD
|
Operating Expenses
|
-24.8B
USD
|
Operating Income
|
11.5B
USD
|
Other Expenses
|
-20.5B
USD
|
Net Income
|
-8.9B
USD
|
BMY Profitability Score
Profitability Due Diligence
Bristol-Myers Squibb Co's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Score
Bristol-Myers Squibb Co's profitability score is 54/100. The higher the profitability score, the more profitable the company is.
BMY Solvency Score
Solvency Due Diligence
Bristol-Myers Squibb Co's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Score
Bristol-Myers Squibb Co's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BMY Price Targets Summary
Bristol-Myers Squibb Co
According to Wall Street analysts, the average 1-year price target for
BMY
is 60.92 USD
with a low forecast of 33.43 USD and a high forecast of 73.5 USD.
Dividends
Current shareholder yield for BMY is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BMY
stock under the Base Case scenario is
72.82
USD.
Compared to the current market price of 59.01 USD,
Bristol-Myers Squibb Co
is
Undervalued by 19%.